Evergreen Capital Management LLC Grows Position in Becton, Dickinson and Company (NYSE:BDX)

Evergreen Capital Management LLC lifted its stake in Becton, Dickinson and Company (NYSE:BDX) by 266.1% in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 49,059 shares of the medical instruments supplier’s stock after acquiring an additional 35,657 shares during the quarter. Evergreen Capital Management LLC’s holdings in Becton, Dickinson and Company were worth $11,466,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds have also recently made changes to their positions in the stock. Livelsberger Financial Advisory bought a new stake in Becton, Dickinson and Company in the 4th quarter worth approximately $27,000. OLD Point Trust & Financial Services N A purchased a new stake in Becton, Dickinson and Company during the fourth quarter valued at $29,000. Scarborough Advisors LLC bought a new position in Becton, Dickinson and Company in the fourth quarter valued at about $32,000. Rise Advisors LLC purchased a new position in Becton, Dickinson and Company in the first quarter worth about $38,000. Finally, ICA Group Wealth Management LLC bought a new stake in shares of Becton, Dickinson and Company during the 4th quarter valued at about $42,000. 86.97% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

BDX has been the topic of a number of research reports. Raymond James dropped their price objective on shares of Becton, Dickinson and Company from $275.00 to $270.00 and set an “outperform” rating on the stock in a report on Friday, August 2nd. StockNews.com raised shares of Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a research report on Thursday, August 8th. Citigroup decreased their target price on Becton, Dickinson and Company from $260.00 to $255.00 and set a “neutral” rating on the stock in a report on Wednesday, July 10th. Stifel Nicolaus boosted their price target on Becton, Dickinson and Company from $270.00 to $280.00 and gave the company a “buy” rating in a report on Friday, July 26th. Finally, Evercore ISI lowered their price objective on Becton, Dickinson and Company from $290.00 to $285.00 and set an “outperform” rating on the stock in a research report on Tuesday, July 2nd. One investment analyst has rated the stock with a hold rating and eight have assigned a buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $279.50.

Becton, Dickinson and Company Stock Performance

NYSE:BDX opened at $233.50 on Monday. The company has a debt-to-equity ratio of 0.70, a current ratio of 1.85 and a quick ratio of 1.36. The company has a market cap of $67.48 billion, a price-to-earnings ratio of 51.43, a PEG ratio of 1.91 and a beta of 0.42. Becton, Dickinson and Company has a 1 year low of $218.75 and a 1 year high of $269.52. The stock’s 50 day simple moving average is $235.51 and its two-hundred day simple moving average is $235.54.

Becton, Dickinson and Company (NYSE:BDX) last released its quarterly earnings data on Thursday, August 1st. The medical instruments supplier reported $3.50 EPS for the quarter, beating the consensus estimate of $3.31 by $0.19. Becton, Dickinson and Company had a net margin of 7.13% and a return on equity of 14.49%. The business had revenue of $4.99 billion during the quarter, compared to analyst estimates of $5.08 billion. During the same quarter last year, the business earned $2.96 earnings per share. Becton, Dickinson and Company’s quarterly revenue was up 2.3% compared to the same quarter last year. As a group, equities analysts anticipate that Becton, Dickinson and Company will post 13.1 earnings per share for the current fiscal year.

Becton, Dickinson and Company Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, September 30th. Shareholders of record on Monday, September 9th will be paid a dividend of $0.95 per share. The ex-dividend date is Monday, September 9th. This represents a $3.80 annualized dividend and a yield of 1.63%. Becton, Dickinson and Company’s payout ratio is currently 83.70%.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.